Karen Gustavson

Cooley advised Outpace Bio, a cell therapy company using unrivaled artificial intelligence-powered protein design to program immune cells for improved function inside patients battling solid tumors, on its $144 million oversubscribed Series B financing.

Cooley advised Rasa, a leading generative conversational artificial intelligence platform, on its $30 million Series C financing.

Cooley advised Kimia Therapeutics on its $55 million Series A financing. Partner Josh Seidenfeld led the Cooley team advising Kimia Therapeutics, which is a drug discovery platform that uncovers novel biological insights through precision chemistry and machine learning.

Read more

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.

Cooley advised NVIDIA on its registered debt offering of $5 billion aggregate principal amount of investment grade senior unsecured notes. The offering consisted of $1.25 billion aggregate principal amount of 0.309% notes due 2023; $1.25 billion aggregate principal amount of 0.584% notes due 2024; $1.25 billion aggregate principal amount of 1.550% notes due 2028; and $1.25 billion aggregate principal amount of 2.000% notes due 2031. Partners Michael Tollini, Mischi a Marca, Jason Savich, Eric Jensen and John McKenna led the Cooley team advising NVIDIA.